

Haili Qian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7493103/publications.pdf>

Version: 2024-02-01

35
papers

922
citations

516710

16
h-index

477307

29
g-index

36
all docs

36
docs citations

36
times ranked

1264
citing authors

#	ARTICLE	IF	CITATIONS
1	Upregulation of MTA1 in Colon Cancer Drives A CD8+ T Cell-Rich But Classical Macrophage-Lacking Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2022, 12, 825783.	2.8	4
2	Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER2-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients. <i>Cancer Medicine</i> , 2022, , .	2.8	8
3	The role of RARRES2 in regulating lipid metabolic reprogramming in the development of brain metastases in triple negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13047-e13047.	1.6	0
4	MTA1: A Vital Modulator in Prostate Cancer. <i>Current Protein and Peptide Science</i> , 2022, 23, 456-464.	1.4	2
5	Cancer metastasis-associated protein 1 localizes to the nucleolus and regulates pre-rRNA synthesis in cancer cells. <i>Journal of Cellular Biochemistry</i> , 2021, 122, 180-188.	2.6	4
6	Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. <i>Leukemia</i> , 2021, 35, 312-332.	7.2	151
7	CDK12 inhibition enhances sensitivity of HER2+ breast cancers to HER2-tyrosine kinase inhibitor via suppressing PI3K/AKT. <i>European Journal of Cancer</i> , 2021, 145, 92-108.	2.8	24
8	Expression and clinical prognostic value of m6A RNA methylation modification in breast cancer. <i>Biomarker Research</i> , 2021, 9, 28.	6.8	13
9	The emerging role of RNA N6-methyladenosine methylation in breast cancer. <i>Biomarker Research</i> , 2021, 9, 39.	6.8	22
10	Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 602222.	2.8	9
11	The molecular tumor burden index as a response evaluation criterion in breast cancer. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 251.	17.1	19
12	Comprehensive analysis reveals GRP94 is associated with worse prognosis of breast cancer. <i>Translational Cancer Research</i> , 2021, 10, 298-309.	1.0	2
13	Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. <i>International Journal of Cancer</i> , 2020, 146, 1359-1368.	5.1	55
14	MTA1 promotes tumorigenesis and development of esophageal squamous cell carcinoma via activating the MEK/ERK/p90RSK signaling pathway. <i>Carcinogenesis</i> , 2020, 41, 1263-1272.	2.8	11
15	A TGF- β 2-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis. <i>Oncogene</i> , 2020, 39, 2125-2139.	5.9	69
16	The Clinical Characteristics of Endometrial Cancer With Extraperitoneal Metastasis and the Value of Surgery in Treatment. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094578.	1.9	13
17	Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. <i>Nature Communications</i> , 2020, 11, 4455.	12.8	20
18	Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 59.	5.2	32

#	ARTICLE	IF	CITATIONS
19	The characteristics of isolated para-aortic lymph node metastases in endometrial cancer and their prognostic significance. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093303.	3.2	9
20	Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. <i>Breast</i> , 2020, 52, 17-22.	2.2	12
21	The clinical characteristics and prognosis of endometrial carcinomas that occur after breast cancer: does hormone receptor status of breast cancer matter?. <i>Archives of Gynecology and Obstetrics</i> , 2019, 300, 1399-1404.	1.7	5
22	Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study. <i>BMC Cancer</i> , 2019, 19, 442.	2.6	26
23	Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2018, 99, 608-614.	5.6	8
24	Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1039-1039.	1.6	4
25	Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis. <i>Scientific Reports</i> , 2017, 7, 5995.	3.3	25
26	Landscape of somatic mutations in different subtypes: Advanced breast cancer with circulating tumour DNA analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23039-e23039.	1.6	0
27	ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. <i>Oncotarget</i> , 2016, 7, 66020-66031.	1.8	75
28	MTA1 regulates higher-order chromatin structure and histone H1 chromatin interaction in vivo. <i>Molecular Oncology</i> , 2015, 9, 218-235.	4.6	20
29	Metastasis-associated gene 1 promotes invasion and migration potential of laryngeal squamous cell carcinoma cells. <i>Oncology Letters</i> , 2014, 7, 399-404.	1.8	10
30	Subcellular localization of MTA proteins in normal and cancer cells. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 843-856.	5.9	36
31	Enriched CD44+/CD24 ^{low} population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). <i>Cancer Letters</i> , 2014, 353, 153-159.	7.2	113
32	The subcellular distribution and function of MTA1 in cancer differentiation. <i>Oncotarget</i> , 2014, 5, 5153-5164.	1.8	37
33	RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model. <i>Biology of the Cell</i> , 2007, 99, 573-581.	2.0	36
34	The therapy and mechanisms of replication-deficient recombinant adenovirus Ad-p14ARF in hepatocellular carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2007, 6, 22-26.	0.1	0
35	Reduced MTA1 Expression by RNAi Inhibits in Vitro Invasion and Migration of Esophageal Squamous Cell Carcinoma Cell Line. <i>Clinical and Experimental Metastasis</i> , 2005, 22, 653-662.	3.3	48